The stock of Editas Medicine Inc (NASDAQ:EDIT) is a huge mover today! About 366,112 shares traded hands or 9.08% up from the average. Editas Medicine Inc (NASDAQ:EDIT) has declined 64.25% since April 8, 2016 and is downtrending. It has underperformed by 69.90% the S&P500.
The move comes after 9 months positive chart setup for the $586.95 million company. It was reported on Nov, 10 by Barchart.com. We have $19.11 PT which if reached, will make NASDAQ:EDIT worth $140.87M more.
According to Zacks Investment Research, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.”
More notable recent Editas Medicine Inc (NASDAQ:EDIT) news were published by: Bostonglobe.com which released: “Editas Medicine raises $94.4 million in year’s first IPO” on February 02, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on January 06, 2016, Ibtimes.com published: “Google-Backed Startup Editas Medicine Becomes First Gene Editing Company To …” on January 05, 2016. More interesting news about Editas Medicine Inc (NASDAQ:EDIT) were released by: Finance.Yahoo.com and their article: “Editas Medicine Expands Senior Management Team” published on October 03, 2016 as well as Globenewswire.com‘s news article titled: “Editas Medicine Appoints Akshay Vaishnaw, M.D., Ph.D., to its Board of Directors” with publication date: July 29, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.